FDA accepted an RTOR sBLA and granted priority review for zanidatamab-hrii combinations as first-line therapy in HER2+ ...
Rusfertide may reduce phlebotomy needs in polycythemia vera, offering a convenient weekly self-injection option that could ...
Longer follow-up from the NMDP's ACCESS trial emphasizes the opportunity to use mismatched stem cell donors in more diverse ...
A new Bayesian statistical framework uses the residual cancer burden score to better predict long-term survival in breast ...
The investigational agent IMNN-001 is demonstrating promising potential to extend survival in patients with advanced ovarian ...
Rashmi Chugh, MD, of the University of Michigan, outlines a strategic roadmap for the future development of ozekibart in ...
Despite advances in immunotherapy and evolving treatment guidelines, many patients never make it to later lines of therapy, ...
Rashmi Chugh, MD, discusses the early outcomes of a trial of ozekibart plus chemotherapy in Ewing sarcoma. Rashmi Chugh, MD, ...
As Dr Wang explains, the combination of robust efficacy, manageable toxicity, and longer follow-up—along with pooled data ...
In this phase 1 trial (NCT03715933), ozekibart is paired with the established chemotherapy duo of temozolomide and irinotecan ...
As regulators examine the on-body injector used with isatuximab in multiple myeloma, Sikander Ailawadhi, MD, provides ...
During a live event, Caitlin Costello, MD, discussed the AQUILA trial and its potential impact on treatment for high-risk smoldering myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results